# Nuclide record pancreatic-net (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/pancreatic-net/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "pancreatic-net" ;
  schema:name "Pancreatic neuroendocrine tumours"@en ;
  schema:alternateName "pNET"@en, "Islet cell tumour"@en, "Pancreatic NET"@en, "Insulinoma"@en, "Gastrinoma"@en, "Non-functioning pancreatic neuroendocrine tumour"@en ;
  schema:description "Pancreatic neuroendocrine tumours arise from the hormone-producing islet cells of the pancreas and behave very differently from ordinary pancreatic cancer, often growing for years. Surgery cures localised tumours; advanced disease is treated in sequence with somatostatin analogues, lutetium-177 dotatate, targeted tablets and oral chemotherapy, and a minority secrete insulin or gastrin."@en ;
  schema:url <https://nuclide.cc/indications/pancreatic-net/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pancreatic_neuroendocrine_tumor> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1009290>, <https://doi.org/10.1056/NEJMoa1003825>, <https://doi.org/10.1056/NEJMoa2403991>, <https://en.wikipedia.org/wiki/Pancreatic_neuroendocrine_tumor> ;
  nuclide:tag "subtype-page", "endocrine" ;
  nuclide:related <https://nuclide.cc/indications/grade-3-net/>, <https://nuclide.cc/indications/lung-net/>, <https://nuclide.cc/indications/small-intestinal-net/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:technologies <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/radioembolisation-tare/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:drugs <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/everolimus/>, <https://nuclide.cc/drugs/sunitinib/>, <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/drugs/ga68-dotatate/>, <https://nuclide.cc/drugs/itm-11/> ;
  nuclide:terms <https://nuclide.cc/terms/net-grade-ki67/>, <https://nuclide.cc/terms/prrt-term/> ;
  nuclide:trials <https://nuclide.cc/trials/radiant-3-4/>, <https://nuclide.cc/trials/cabinet/>, <https://nuclide.cc/trials/nct03972488/>, <https://nuclide.cc/trials/netter-1/>, <https://nuclide.cc/trials/compete/>, <https://nuclide.cc/trials/nct04919226/> ;
  nuclide:keyPapers <https://nuclide.cc/key-papers/paper-netter-2-lancet-2024/>, <https://nuclide.cc/key-papers/paper-cabinet-cabozantinib-nejm-2024/> ;
  nuclide:pipeline <https://nuclide.cc/drugs/itm-11/>, <https://nuclide.cc/trials/compete/>, <https://nuclide.cc/trials/nct04919226/>, <https://nuclide.cc/drugs/ryz101/>, <https://nuclide.cc/trials/action-1/>, <https://nuclide.cc/drugs/alphamedix/>, <https://nuclide.cc/trials/nct05884255/>, <https://nuclide.cc/ideas/idea-net-dosimetry-prrt/> ;
  nuclide:standardOfCare <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/drugs/ga68-dotatate/>, <https://nuclide.cc/terms/net-grade-ki67/>, <https://nuclide.cc/drugs/everolimus/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/trials/nct03972488/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/everolimus/>, <https://nuclide.cc/trials/radiant-3-4/>, <https://nuclide.cc/drugs/sunitinib/>, <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/trials/cabinet/>, <https://nuclide.cc/technologies/radioembolisation-tare/> .